[1] 李芳,陶晨,杜建霞. 恩替卡韦治疗慢性乙型重型肝炎的近期疗效观察. 实用肝脏病杂志,2008,11（6）：383-384.
[2] 刘克洲,倪勤,侯伟. 重型肝炎治疗的若干问题. 内科急危重症杂志,2005,11（1）：13-16.
[3] 中华肝脏病杂志编辑部. 慢性乙型肝炎抗病毒治疗重在规范：口服核苷类药物的临床应用原则.中华肝脏病杂志,2008,16（5）：335-340.
[4] 中华医学会传染病与寄生虫病学分会、肝病学分会. 病毒性肝炎防治方案. 中华肝脏病杂志,2008,8:324-329.
[5] Mindikoglu AL,Regev A,Schiff ER.Hepatitis B virus reactivation after cytotoxic chemotherapy:the disease and its prevention.Clin Gastroenterol Hepatol,2006,14:1076-1081.
[6] Honkoop P,DE Man RA.Entecavir:a potent new antiviral drug for hepatitis B.Expert Opin Investig Drugs,2003,12:683-688.
[7] Tenney DJ,Rose RE,Baldick CJ,et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology,2009,49:1503-1514.
[8] Colonno RJ,Rose RE,Pokornowski K,et al. Assessment at three years shows high barrier to treated nucleoside naive patients while resistance emergence increases over time in lamivudine refractory patients. Hepatology,2006,44 （Suppl 1）:229A-230A.
[9] 罗玮敏,张迎春,刘中景. 恩替卡韦治疗慢性乙型肝炎的早期临床观察. 临床肝胆病杂志,2008,24（1）:26-28.
[10] Sue YM,Cheng CF,Chang CC,et al. Antioxidation and anti-inflammation by haem oxygenase-1 contribute to proteltion by tetramethylpyrazine against gentamicin-induced apoptosis in murine renal tubular cells. Nephrol Dial Transplant,2009;24:769-77.
[11] 梁爱群. 川芎嗪的药理及机理研究.时珍国医国药,2005;16:532-533.
[12] 刘梁英,李孝生,万晓强. 川芎嗪和太黄酸对肝细胞增殖和凋亡的影响. 中华肝脏病杂志,2006;14:219-222.
[13] 朱上林. 川芎嗪对肝缺血-再灌注损伤防护作用的试验研究. 中华消化杂志,1992,15（3）:139-141.
[14] 邱夏地,顾国妹,施建平,等. 川芎嗪联合内镜下曲张静脉套扎术预防食管静脉破裂出血的临床研究. 肝脏,2002,20（1）:5-7.
[15] 胡万峰,张莉静. 恩替卡韦治疗慢性乙型重型肝炎中期患者近期疗效分析. 江西医药,2008,43（4）：320-321. |
